Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | MST1R |
| Variant | dec exp |
| Impact List | none |
| Protein Effect | no effect |
| Gene Variant Descriptions | MST1R (RON) dec exp indicates decreased expression of the Mst1r (Ron) protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified. |
| Associated Drug Resistance | |
| Category Variants Paths |
MST1R dec exp |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MST1R dec exp | bladder carcinoma | predicted - sensitive | Doxorubicin | Preclinical - Cell culture | Actionable | In a preclinical study, knockdown of MST1R (RON) increased sensitivity of a bladder carcinoma cell line to Adriamycin (doxirubicin) under hypoxia in culture, resulting in decreased cell survival (PMID: 26772202). | 26772202 |
| MST1R dec exp | bladder carcinoma | predicted - sensitive | Epirubicin | Preclinical - Cell culture | Actionable | In a preclinical study, knockdown of MST1R (RON) increased sensitivity of a bladder carcinoma cell line to Ellence (epirubicin) under hypoxia in culture, resulting in decreased cell survival (PMID: 26772202). | 26772202 |